The European Society of Cardiology hosts the world’s largest and most influential cardiovascular event every year in August. This year ESC Congress 2014 sees record numbers of hot line sessions and abstracts submitted and the congress is on track to host the largest number of delegates in its history. ESC Congress 2014, will take place in Barcelona, Spain, from 30 August to 3 September. This year's event has attracted record submissions for both the new study abstract and late-breaking Hot Line sessions, which, says Professor Keith Fox, Chair of the Congress Programme Committee, will ensure another year of high quality presentations reflecting this year's congress spotlight, "innovation and the heart".
· At this year’s Congress, Biosensewebster (Biosensewebster-ESC2014) is supporting a symposium: Rhythm Management of the Atrial Fibrillation Patien which aims to educate attendees about the the 2012 ESC guidelines: Best practice for rhythm management of Atrial Fibrillation patients in the real world scenario, including identifying best patient selection for catheter ablation. It also aims to foster a “shared care” approach between the electrophysiologist and cardiologist. Interested parties can register by visiting biosensewebster-ESC2014 site.
Delegates at the ESC 2014 Conference will also hear the result of eagerly anticipated trials such as the SOLID-TIMI 52 trial of the PLA2 inhibitor darapladib. Previous studies have reported its effects in stable coronary artery disease but this is the first trial in myocardial infarction. Innovative treatment approaches featured in the hot lines include vagal stimulation for systolic heart failure (NECTAR-HF), nitric oxide inhalation to reduce reperfusion injury in STEMI (NOMI) and the novel anti-Xa rivaroxaban for cardioversion (X-VERT). ESC 2014 Conference will also see record numbers of abstract submissions, totalling 11,444. “Innovation and the heart” is the congress spotlight. It will explore innovations in science, the clinical application of studies and trials, the use of existing therapies, the assessment of impact, and in education.
No comments:
Post a Comment